H_2受体阻滞剂雷尼替丁(Ranitidine)问世以来,世界各国约有2,500万病例曾应用此药。1986年4月下旬,在东京召开了有关雷尼替丁的讨论会,会上日本几十位专家就本药的基础及临床应用问题进行了讨论,兹将临床应用部分归纳译述如下。一、雷尼替丁对急慢性溃疡的疗效在此次讨论中报告了雷尼替丁对急性胃粘膜病变、返流性(糜烂性)食道炎、急慢性溃疡的疗效。多田正弦氏报告本品对急性溃疡的治愈率,6周内可达86％。多田氏 Since the advent of the H 2 blocker Ranitidine, about 25 million people in all countries in the world have used the drug. In late April 1986, a seminar on ranitidine was held in Tokyo. At the meeting, dozens of Japanese experts discussed the basis and clinical application of the drug. The clinical application part is summarized as follows. First, the efficacy of ranitidine on acute and chronic ulcers In this discussion, ranitidine reported on acute gastric mucosal lesions, reflux (erosive) esophagitis, acute and chronic ulcer efficacy. Tada sinus report this product cure rate of acute ulcers, up to 86% within 6 weeks. Tadashi